Total Revenue
Gilead Sciences Total Revenue decreased by 12.2% to $6.96B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 4.4%, from $6.67B to $6.96B. Over 4 years (FY 2021 to FY 2025), Total Revenue shows relatively stable performance with a 1.9% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates market expansion or higher demand, while a decrease may signal market saturation or competitive pressure.
Detailed definition
Total revenue represents the gross inflow of economic benefits arising from the ordinary operating activities of the com...
Peer comparison
Standard across all public companies; peers in the medical device and diagnostics sector typically show steady growth correlated with product adoption.
total_revenueHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $6.22B | $7.42B | $7.24B | $6.59B | $6.26B | $7.04B | $7.39B | $6.35B | $6.60B | $7.05B | $7.11B | $6.69B | $6.95B | $7.55B | $7.57B | $6.67B | $7.08B | $7.77B | $7.93B | $6.96B |
| QoQ Change | — | +19.4% | -2.4% | -9.0% | -5.0% | +12.5% | +4.9% | -14.0% | +3.9% | +6.8% | +0.9% | -6.0% | +4.0% | +8.5% | +0.3% | -11.9% | +6.2% | +9.7% | +2.0% | -12.2% |
| YoY Change | — | — | — | — | +0.7% | -5.1% | +2.0% | -3.6% | +5.4% | +0.1% | -3.7% | +5.3% | +5.4% | +7.0% | +6.4% | -0.3% | +1.8% | +3.0% | +4.7% | +4.4% |
Product Breakdown
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Biktarvy | $3.23B | $3.47B | $3.77B | $3.15B | $3.53B | $3.69B | $3.97B | $3.36B |
| Descovy | $485.00M | $586.00M | $616.00M | $586.00M | $653.00M | $701.00M | $818.00M | $807.00M |
| Trodelvy | — | — | — | $293.00M | $364.00M | $357.00M | $383.00M | $402.00M |
| Yescarta | $414.00M | $387.00M | $389.00M | $386.00M | $393.00M | $349.00M | $367.00M | $332.00M |
| Sofosbuvir/Velpatasvir | — | — | — | $346.00M | $342.00M | $309.00M | $275.00M | $283.00M |
| Genvoya | $440.00M | $449.00M | $470.00M | $364.00M | $377.00M | $377.00M | $380.00M | $264.00M |
| Vemlidy | — | — | — | $252.00M | $252.00M | $280.00M | $286.00M | $237.00M |
| Odefsey | $315.00M | $326.00M | $337.00M | $281.00M | $298.00M | $277.00M | $311.00M | $221.00M |
| Yeztugo | — | — | — | — | — | — | — | $166.00M |
| Veklury | — | — | — | $302.00M | $121.00M | $277.00M | $211.00M | $144.00M |
| AmBisome | $151.00M | $130.00M | $108.00M | $139.00M | $129.00M | $123.00M | $118.00M | $138.00M |
| Symtuza - Revenue share | — | — | — | $114.00M | $124.00M | $124.00M | $133.00M | $138.00M |
| Livdelzi | — | — | — | — | — | — | — | $133.00M |
| Other Liver Disease | — | — | — | $161.00M | $201.00M | $231.00M | $281.00M | $114.00M |
| Tecartus | — | — | — | $78.00M | $92.00M | $83.00M | $91.00M | $75.00M |
| Other HIV | — | — | — | $91.00M | $107.00M | $112.00M | $190.00M | $73.00M |
| Other | $130.00M | $71.00M | $75.00M | $70.00M | $73.00M | $61.00M | $86.00M | $58.00M |
| Royalty, contract and other revenues | $41.00M | $30.00M | $34.00M | $54.00M | $27.00M | $424.00M | $22.00M | $14.00M |
| Total Liver Disease | $832.00M | $733.00M | — | — | — | — | — | — |
| Total Oncology | $841.00M | $816.00M | — | — | — | — | — | — |
| Total | $6.95B | $7.55B | $7.57B | $6.67B | $7.08B | $7.77B | $7.93B | $6.96B |
Geographic Breakdown
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Europe | $1.13B | $1.17B | $1.18B | $1.08B | $1.19B | $1.56B | $1.24B | $1.14B |
| Rest of World | — | — | — | $915.00M | $842.00M | $933.00M | $813.00M | $889.00M |
| Total | $6.95B | $7.55B | $7.57B | $6.67B | $7.08B | $7.77B | $7.93B | $6.96B |
Total Revenue at Other Companies
Frequently Asked Questions
- What is Gilead Sciences's total revenue?
- Gilead Sciences (GILD) reported total revenue of $6.96B in Q1 2026.
- How has Gilead Sciences's total revenue changed year-over-year?
- Gilead Sciences's total revenue increased by 4.4% year-over-year, from $6.67B to $6.96B.
- What is the long-term trend for Gilead Sciences's total revenue?
- Over 4 years (2021 to 2025), Gilead Sciences's total revenue has grown at a 1.9% compound annual growth rate (CAGR), from $27.31B to $29.44B.
- What does total revenue mean?
- The total amount of money a company brings in from its primary business activities before any expenses.